Broad-spectrum cation channel inhibition by LOE 908 MS reduces infarct volume in vivo and postmortem in focal cerebral ischemia in the rat.
Cation channels conduct calcium, sodium and potassium, cations that are likely deleterious in the evolution of focal ischemic injury. We studied the effects of a novel, broad-spectrum inhibitor of several cation channels, LOE 908 MS, on acute ischemic lesion development with diffusion-weighted magnetic resonance imaging (DWI) and on cerebral perfusion with perfusion imaging (PI) in vivo and on cerebral infarct size using 2,3,5-triphenyltetrazolium chloride (TTC) staining postmortem. A total of 18 male Sprague-Dawley rats underwent 90 min of middle cerebral artery occlusion (MCAO) and were randomly and blindly assigned to either LOE 908 MS or vehicle starting 30 min after inducing focal ischemia and continuing for 4 h. Whole-brain DWI and multislice PI were done before initiation of treatment and repeated frequently for the next 3.5 h. DWI-derived lesion volume at 4 h showed a significant difference in favor of the drug treated group (P=0.03), whereas PI-derived perfusion deficit volumes did not significantly differ between the groups. The postmortem infarct volume at 24 h was significantly attenuated in the treated group in comparison to controls (P=0.0001) and neurological score was significantly better in the treated group (P<0.02). Blocking several distinct cation channels with LOE 908 MS significantly reduced infarct size and improved neurological outcome without observable adverse effects in this focal ischemia model.
Tatlisumak
T
T
Department of Neurology, Helsinki University Central Hospital, Haartmaninkatu 4, 00290, Helsinki, Finland. turgut.tatlisumak@hus.fi
Carano
R A
RA
Takano
K
K
Meiler
M R
MR
Li
F
F
Sotak
C H
CH
Arndts
D
D
Pschorn
U
U
Fisher
M
M
D000081:Acetamides / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D002545:Brain Ischemia / Q000150:complications / Q000473:pathology*; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000166:cytology / Q000502:physiology; D002544:Cerebral Infarction / Q000473:pathology* / Q000517:prevention & control; D007473:Ion Channels / Q000187:drug effects*; D007546:Isoquinolines / Q000494:pharmacology* / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D011180:Postmortem Changes; D051381:Rats; D017207:Rats, Sprague-Dawley; D014701:Veratridine / Q000494:pharmacology
D000081:Acetamides; D007473:Ion Channels; D007546:Isoquinolines; C081356:LOE 908; D014701:Veratridine